



Attorney Docket No. 0800-0033

PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 3/18/04.

By: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of IKEDA et al.

Serial No.: 10/690,063

Examiner: Not Assigned

Confirmation No.:

Art Unit: 1632

Filed: October 20, 2003

For: METHODS FOR TREATING AND PREVENTING VASCULAR DISEASE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Enclosed is an Information Disclosure Statement and accompanying Form PTO/SB/08A for the above-identified patent application.

- ☒ [X] In accordance with 37 C.F.R. §1.97(b), no additional fee for submission of the IDS is required.
- ☐ [] In accordance with 37 C.F.R. §1.97(c), also enclosed is:
 - ☐ [] the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p); or
 - ☐ [] a statement as specified in 37 C.F.R. §1.97(e).
- ☐ [] In accordance with 37 C.F.R. §1.97(d), a statement as specified in 37 C.F.R. §1.97(e) and the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) are also enclosed.
- ☐ [] Check No. ___ in the amount of \$___ for the total fee is attached.

☒ [X] A return receipt postcard is also enclosed.

☐ [] Please charge \$_____ to Deposit Account No. 18-1648 for the total fee.
This paper is being submitted in duplicate.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 18-1648.

Dated: 3/18/04

Respectfully submitted,

Robins & Pasternak LLP
1731 Embarcadero Road, Suite 230
Palo Alto, CA 94303
Tel: (650) 493-3400
Fax: (650) 493-3440

By:



Roberta L. Robins

Reg. No. 33,208

- ☐ Enclosed is a copy of a non-English publication(s) _____. Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).
- ☐ Enclosed is a copy of a non-English publication(s) _____. English language publication ____ (copy enclosed) claims priority from this non-English publication.
- ☐ Enclosed is an explanation of non-English publication(s) _____ for which an English translation is not available.
- ☐ Enclosed is an English translation of non-English publication(s) _____ cited in the attached Form PTO/SB/08A.
- ☐ Enclosed is a copy of pending patent Application Serial No. _____.

This Information Disclosure Statement is filed within any one of the following time periods:

- ☐ within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);
- ☐ within three months from the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in this international application;
- ☒ before the mailing date of a first office action on the merits; or
- ☐ before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. §1.114.

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08A to the undersigned.

Dated: 3/18/04

Respectfully submitted,

Robins & Pasternak LLP
1731 Embarcadero Road, Suite 230
Palo Alto, CA 94303
Tel: (650) 493-3400
Fax: (650) 493-3440

By: _____

Roberta L. Robins
Reg. No. 33,208

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/690,063
				Filing Date	October 20, 2003
				First Named Inventor	Ikeda et al.
				Group Art Unit	1632
Examiner Name	Not Assigned				
Sheet	2	of	2	Attorney Docket Number	0800-0033

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C1	Boehler et al., "ADENOVIRUS-MEDIATED INTERLEUKIN-10 GENE TRANSFER INHIBITS POST-TRANSPLANT FIBROUS AIRWAY OBLITERATION IN AN ANIMAL MODEL OF BRONCHIOLITIS OBLITERANS," <i>Hum. Gene Ther.</i> 9:541-551 (1998)		
	C2	Brauner et al., "INTRACORONARY ADENOVIRUS-MEDIATED TRANSFER OF IMMUNOSUPPRESSIVE CYTOKINE GENES PROLONGS ALLOGRAFT SURVIVAL," <i>J. Thoracic Cardiovasc. Surg.</i> 114:923-933 (1997)		
	C3	Ghivizzani et al., "GENE THERAPY APPROACHES FOR TREATING RHEUMATOID ARTHRITIS," <i>Clin. Orthop.</i> 379suppl.:S288-299 (2000)		
	C4	C.P. Hodgson, "THE VECTOR VOID IN GENE THERAPY," <i>Biotechnology</i> 13:222-225 (1995)		
	C5	Lindsay et al., "THE PREVENTION AND TREATMENT OF MURINE COLITIS USING GENE THERAPY WITH ADENOVIRAL VECTORS ENCODING IL-10 ^{1b} ," <i>J. Immunol.</i> 166:7625-7633 (2001)		
	C6	Meng et al., "KERATINOCYTE GENE THERAPY FOR SYSTEMIC DISEASES," <i>J. Clin. Invest.</i> 101:1462-1467 (1998)		
	C7	Morrison et al., "INTERLEUKIN-10 GENE THERAPY-MEDIATED AMELIORATION OF BACTERIAL PNEUMONIA," <i>Infect. Immun</i> 30(8):4752-4758 (2000)		
	C8	Xing et al., "ADENOVIRAL VECTOR-MEDIATED INTERLEUKIN-10 EXPRESSION IN VIVO: INTRAMUSCULAR GENE TRANSFER INHIBITS CYTOKINE RESPONSES IN ENDOTOXEMIA," <i>Gene Ther.</i> 4:140-149 (1997)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² Applicant is to place a check mark here if English language Translation attached.